anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a method for coupling an antibody and an effector molecule at a fixed point and a bridging molecule thereof. The bridging molecule provided by the invention mainly comprises an antibody binding part (a molecule A modified with an activating group, wherein the molecule A can be specifically bound with an antibody Fc segment, and the activating group can enable the molecule A to be covalently linked with the antibody Fc segment) and an effector molecule binding part (a molecule B with a linker, wherein the molecule B can be bound with an effector molecule and the linker can be linked with the molecule A in the antibody binding part, or a molecule B without the linker, wherein the molecule B can be bound with the effector molecule and can also be linked with the molecule A in the antibody binding part). The bridging molecules of the present invention have the following advantages: specificity, i.e., binding to the Fc fragment of the antibody, does not affect the recognition of the antibody to the bound antigen. The universality is that the antibody has the coupling ability with each type of antibody containing Fc structure. Irreversibility, i.e. after the antibody-bridging molecule-effector molecule complex is formed, the complex cannot be dissociated or is extremely difficult to dissociate, the stability is strong, and the non-specific background is low.
The rapid technological advancements in cardiac implantable electronic devices such as pacemakers, implantable cardioverter defibrillators, and loop recorders, coupled with a rise in the number of patients with these devices, necessitate an updated clinical framework for periprocedural management. The introduction of leadless pacemakers, subcutaneous and extravascular defibrillators, and novel device communication protocols underscores the imperative for clinical updates. This scientific statement provides an inclusive framework for the periprocedural management of patients with these devices, encompassing the planning phase, procedure, and subsequent care coordinated with the primary device managing clinic. Expert contributions from anesthesiologists, cardiac electrophysiologists, and cardiac nurses are consolidated to appraise current evidence, offer patient and health system management strategies, and highlight key areas for future research. The statement, pertinent to a wide range of health care professionals, underscores the importance of quality care pathways for patient safety, optimal device function, and minimization of hemodynamic disturbances or arrhythmias during procedures. Our primary objective is to deliver quality care to the expanding patient cohort with cardiac implanted electronic devices, offering direction in the era of evolving technologies and laying a foundation for sustained education and practice enhancement.
Protein derivatives are prepared by reacting a human serologically compatible protein with an anhydride or chloride of an aliphatic polycarboxylic acid in an aqueous medium in which the pH is maintained between 6 and 12, thereafter, while maintaining the temperature of the mixture above 5 DEG  C., adjusting the acidity of the reaction mixture to a pH of below 6 and approximating the isoelectric point of the protein derivative to precipitate this derivative as a coagulum, separating the coagulum from the reaction mixture and further working up the coagulum to remove therefrom any remaining incompletely reacted protein and any noncoagulated reaction products by reprecipitation of the coagulum from aqueous solution at the isoelectric point of the protein derivative, e.g. with the aid of sodium chloride, methanol, ethanol, isopropanol or acetone.  Suitable compatible proteins are gelatin, human serum albumin, human globulin and human globin, and especially gelatin degraded to an average molecular weight in the range of 15,000 to 36,000.  Specified polycarboxylic acid reactants are succinic, citraconic, itaconic, aconitic and maleic anhydrides and succinyl and fumaryl chlorides. The protein derivatives may be used as blood plasma extenders (see Group VI).  In typical examples: (1) powdered succinic anhydride is slowly added at 36 DEG  C. to a stirred aqueous solution of gelatin, the pH being maintained at 8.5 to 10 by regular additions of aqueous NaOH; the pH of the reacted mixture is then reduced to 2.7 by means of HCl and, on settling, an immiscible bottom layer of oily protein derivative forms which is separated and dissolved in distilled water; the pH of the solution is adjusted to 2.5-3.0 and sodium chloride added to reprecipitate the protein derivative which may be further purified by dialysis to remove entrained salt; (7) fumaryl chloride is reacted with aqueous gelatin following the method of (1), the reacted mixture is then acidified to pH 2.5 and the precipitated protein purified as before.  The mother liquors from the first precipitation of protein derivative may be cooled to precipitate other protein products of lower molecular weight.  Specifications 649,544 and 649,545 are referred to.ALSO:Blood plasma extenders comprise isotonic solutions of protein derivatives prepared by reacting human serologically compatible proteins with an anhydride or chloride of an aliphatic polycarboxylic acid (see Group IV(b)). Specified reactants are gelatin, human serum albumin, human globulin and human globin and succinic, citraconic, itaconic, aconitic and maleic anhydrides and succinyl and fumaryl chlorides.  Specifications 649,544 and 649,545, [both in Group IV(b)], are referred to.
Patients with trauma admitted to San Francisco General Hospital and qualify for the study will be assigned to +fondaparinux and no fondaparinux arms based on guidelines that were developed for and are considered the standard of care for the use of low molecular weight heparin in the same group of patients for the same indication. These guidelines will separate patients at risk for DVT into those that are high risk and very high risk. The primary efficacy outcome measures will be DVT and PE. Presence of DVT will be assessed with serial color flow duplex ultrasound during the patients in hospital stay at weekly intervals up to 3 weeks and when the patient has symptoms of DVT. PE will be diagnosed according to clinical suspicion by the patients treating physicians and subsequent imaging by CT. We plan on enrolling approximately 100 patients in the +fondaparinux and 100 patients in the no fondaparinux arm. We will compare both the incidence of DVT and PE in these groups and to the incidences in the literature and historical controls. A second aim of the study is to evaluate the adverse outcomes such as increased bleeding in patients who receive fondaparinux. A third and final aim of the study is to describe the effect of fondaparinux on antifactor Xa levels in trauma patients.
The present invention relates to a veterinary supplement composition for preventing colic that includes simethicone and optionally sorbitol. The veterinary supplement composition is administered orally by syringe or mixed with animal feed. The veterinary supplement composition can be liquid or powder. Dosage is determined by body weight from about 1 mL per 400 pounds of body weight to about 1.2 mL per 400 pounds of body weight. Palatants can be added to improve animal taste likability. Such Palatants can include mint, apple, cinnamon, peppermint, banana, and others. The oral supplement can also be used in the prevention of colic in horses.
Fifteen subjects with retinal disease. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
Patients with inflammatory liver diseases, particularly alcohol-associated liver disease and metabolic dysfunction-associated fatty liver disease (MAFLD), have higher incidence of infections and mortality rate due to sepsis. The current focus in the development of drugs for MAFLD is the resolution of non-alcoholic steatohepatitis and prevention of progression to cirrhosis. In patients with cirrhosis or alcoholic hepatitis, sepsis is a major cause of death. As the metabolic center and a key immune tissue, liver is the guardian, modifier, and target of sepsis. Septic patients with liver dysfunction have the highest mortality rate compared with other organ dysfunctions. In addition to maintaining metabolic homeostasis, the liver produces and secretes hepatokines and acute phase proteins (APPs) essential in tissue protection, immunomodulation, and coagulation. Inflammatory liver diseases cause profound metabolic disorder and impairment of energy metabolism, liver regeneration, and production/secretion of APPs and hepatokines. Herein, the author reviews the roles of (1) disorders in the metabolism of glucose, fatty acids, ketone bodies, and amino acids as well as the clearance of ammonia and lactate in the pathogenesis of inflammatory liver diseases and sepsis; (2) cytokines/chemokines in inflammatory liver diseases and sepsis; (3) APPs and hepatokines in the protection against tissue injury and infections; and (4) major nuclear receptors/signaling pathways underlying the metabolic disorders and tissue injuries as well as the major drug targets for inflammatory liver diseases and sepsis. Approaches that focus on the liver dysfunction and regeneration will not only treat inflammatory liver diseases but also prevent the development of severe infections and sepsis.
BACKGROUND: Arteriovenous fistula represents the preferred vascular access for patients with kidney failure requiring hemodialysis. Surgeons have traditionally used physical examination to identify the most suitable vessels. This meta-analysis aims to evaluate whether ultrasound mapping should be routinely performed before arteriovenous fistula creation.
METHODS: Medline, Scopus, Web of Science and CENTRAL were systematically searched from inception to November 1, 2022. Randomized controlled trials and cohort studies comparing routine ultrasound mapping to physical examination in terms of arteriovenous fistula patency were included. Meta-analysis was performed by fitting random-effects models. The study protocol has been prospectively registered in PROSPERO (CRD42023402390).
RESULTS: Overall, 18 studies were included, comprising 3655 participants. Routine pre-operative ultrasound mapping was associated with significantly lower rates of primary arteriovenous fistula failure (Risk Ratio-RR: 0.56, 95% confidence intervals-CI: 0.37-0.84, low certainty). A significant outcome was observed by separately pooling randomized controlled trials (RR: 0.37, 95% CI: 0.25-0.54). Routine ultrasound mapping was also associated with significantly higher rates of 1-year primary arteriovenous fistula patency (RR: 1.33, 95% CI: 1.19-1.47, moderate certainty). This effect remained significant in the analysis of randomized controlled trials (RR: 1.26, 95% CI: 1.02-1.56).
CONCLUSIONS: Implementing routine pre-operative ultrasound mapping of vessels is associated with significantly better outcomes in terms of early arteriovenous fistula failure and primary patency rates at 12 months. Further research should confirm the long-term benefits of routine ultrasound examination and evaluate its cost-effectiveness in different populations.
Skeletal muscle has gained recognition as an endocrine organ releasing myokines upon contraction during physical exercise. These myokines exert both local and pleiotropic health benefits, underscoring the crucial role of muscle function in countering obesity and contributing to the overall positive effects of exercise on health. Here, we found that exercise activates muscle p38γ, increasing locomotor activity through the secretion of interleukin-15 (IL-15). IL-15 signals in the motor cortex, stimulating locomotor activity. This activation of muscle p38γ, leading to an increase locomotor activity, plays a crucial role in reducing the risk of diabetes and liver steatosis, unveiling a vital muscle-brain communication pathway with profound clinical implications. The correlation between p38γ activation in human muscle during acute exercise and increased blood IL-15 levels highlights the potential therapeutic relevance of this pathway in treating obesity and metabolic diseases. These findings provide valuable insights into the molecular basis of exercise-induced myokine responses promoting physical activity.
Newly diagnosed PCNSL participants with planned treatment of standard high-dose methotrexate,temozolomide plus rituximab (MT-R) regimen will receive hyperpolarized carbon C 13 pyruvate intravenously (IV) and undergo MRI at baseline and again after three cycles of of standard induction chemotherapy. An optional second HP 13C pyruvate injection and MRI acquisition will be offered on same day following completion of the first scan. Participants in Cohort 2 will also have option to undergo an additional imaging at a later time if the participant's cancer progresses.
BACKGROUND: Children with IgA Vasculitis (IgAV) may develop renal complications, which can impact their long-term prognosis. This study aimed to build a machine learning model to predict renal damage in children with IgAV and analyze risk factors for IgA Vasculitis with Nephritis (IgAVN).
METHODS: 50 clinical indicators were collected from 217 inpatients at our hospital. Six machine learning algorithms-Logistic Regression, Linear Discriminant Analysis, K-Nearest Neighbor, Support Vector Machine, Decision Trees, and Random Forest-were utilized to select the model with the highest predictive performance. A simplified model was developed through feature importance ranking and validated by an additional cohort with 46 patients.
RESULTS: The random forest model had the highest accuracy, precision, recall, F1 score, and area under the curve, with values of 0.91, 0.98, 0.70, 0.79 and 0.94, respectively. The top 11 features according to the importance ranking were anti-streptolysin O, corticosteroids therapy, antihistamine therapy, absolute eosinophil count, immunoglobulin E, anticoagulant therapy, C-reactive protein, prothrombin time, age at onset, D-dimer, recurrence of rash ≥ 3 times. A simplified model using these features demonstrated optimal performance with an accuracy of 84.2%, a sensitivity of 89.4%, and a specificity of 82.5% in external validation. Finally, we provided a web tool based on the simplified model, whose code was published on https://github.com/mulanruo/IgAVN_Prediction .
CONCLUSION: The model based on the random forest algorithm demonstrates good performance in predicting renal damage in children with IgAV, providing a basis for early clinical diagnosis and decision-making.
FIELD: organic chemistry, biochemistry, pharmacy. SUBSTANCE: invention relates to new thienopyrimidines of the formula (I)  , their pharmaceutically acceptable salts eliciting effect of inhibitors of phosphodiesterase V. Invention relates also to method for preparing thienopyrimidines of the formula (I) and their pharmaceutically acceptable salts and pharmaceutical composition based on thereof. In thienopyrimidines of the formula (I) R 1  and R 2  both in common mean alkylene with 3-5 carbon atoms; R 3  and R 4  each independently each of other means hydrogen atom, A, OA or Hal; R 3  and R 4  both in common mean also alkylene with 3-5 carbon atoms, -O-CH 2 -CH 2 , -O-CH 2 -O- or O-CH 2 -CH 2 -O-; X means R 7  or R 5  monosubstituted with R 6 ; R 5  means linear or branched alkylene with 1-10 carbon atoms; R 6  means cycloalkylalkylene with 6-12 carbon atoms; R 7  means COOH, COOA, CONH 2 , CONHA, CON(A) 2  or CN; A means alkyl with 1-6 carbon atoms; Hal means fluorine, chlorine, bromine or iodine atom; m = 1 or 2; n = 1, 2 or 3. Method for preparing compounds of the formula (I) and their salts also involves interaction of compound of the formula (II)   wherein R 1 , R 2  and X have above indicated values and L means Cl, Br, OH, SCH 3  or reactive esterified OH-group with compound of the formula (III)   wherein R 3 , R 4  and n have above indicated value followed by if necessary conversion of one residue X to another residue X in compounds of the formula (I), for example, by hydrolysis of ester group to COOH-group or by conversion of COOH-group to amide or to cyano- group and/or by conversion of compound of the formula (I) to one of its pharmaceutically acceptable salts. Pharmaceutical composition contains at least one compound of the formula (I) and/or one of it physiologically acceptable salts. Prepared compounds can be used for control of cardiovascular system and for treatment and/or therapy in potency disorder, for preparing pharmaceutical composition in form useful for treatment. EFFECT: improved preparing method, valuable medicinal properties. 7 cl, 14 ex
FIELD: medicine. ^ SUBSTANCE: evaluating effectiveness of film coatings in burn wound repair is enabled by determining microorganism sensitivity to chitosan film coatings. An effect of the coating on the wound microflora is evaluated by incubation of the wound microflora and the coating on a nutrient agar medium to be thereafter analysed for microflora sensitivity to the coating by the absence of bacterial growth. The incubation process is performed at 37C for 24 hours. Microorganism sensitivity is evaluated consistently during each period of burn disease, thereafter the coating is replaced by that one considered being the most effective. ^ EFFECT: use of the invention provides higher accuracy of evaluating effectiveness of the chitosan film coating due to sensitivity analysis of microorganism found on surfaces of burn and granulating wounds depending on a pattern of the wound process, severity and depth of the lesion. ^ 1 ex
The clinical presentation of COVID-19 shows high variability among individuals, which is partly due to genetic factors. The OAS1/2/3 cluster has been found to be strongly associated with COVID-19 severity. We examined this locus in the Moroccan population for the occurrence of the critical variant rs10774671 and its respective haplotype blocks. The frequency of single-nucleotide polymorphisms (SNPs) in the cluster of OAS immunity genes in 157 unrelated individuals of Moroccan origin was determined using an in-house exome database. OAS1 exon 6 of 71 SARS-CoV-2-positive individuals with asymptomatic/mild disease and 74 with moderate/severe disease was sequenced by the Sanger method. The genotypic, allelic, and haplotype frequencies of three SNPs were compared between these two groups. Finally, males in our COVID-19 series were genotyped for the Berber-specific marker E-M81. The prevalence of the OAS1 rs10774671-G allele in present-day Moroccans was found to be 40.4%, which is similar to that found in Europeans. However, it was found equally in both the Neanderthal GGG haplotype and the African GAC haplotype, with a frequency of 20% each. These two haplotypes, and hence the rs10774671-G allele, were significantly associated with protection against severe COVID-19 (p = 0.034, p = 0.041, and p = 0.008, respectively). Surprisingly, in men with the Berber-specific uniparental markers, the African haplotype was absent, while the prevalence of the Neanderthal haplotype was similar to that in Europeans. The protective rs10774671-G allele of OAS1 was found only in the Neanderthal haplotype in Berbers, the indigenous people of North Africa, suggesting that this region may have served as a stepping-stone for the passage of hominids to other continents.
A minimum of 162 patients were required, considering an expected Mean Difference of 5 with expected Standard Deviation of 22, confidence level of 95% and power of 80%. Estimating a possible loss of 15%, it was raised to 192. Consecutive identification numbers were assigned and the sample was randomized in six groups of 32 patients according to time and dose of propofol.

Pre-oxygenation was performed until the expired oxygen fraction exceeded 80% and 2 µg/kg of intravenous fentanyl were administered. Depending on the study group, 1 or 2 minutes were allowed to pass and 1, 1.5 or 2 mg/kg of propofol were supplied (prior administration of intravenous lidocaine 0.5 mg/kg). The time in which the BIS dropped below 60 was recorded. If it did not reach that level after two minutes or when it exceeded it but then rose above 60 again, an extra dose of propofol of 0.5 mg/kg was administered. Muscle relaxation was performed with rocuronium 0.6 mg/kg. The patient was manually ventilated until endotracheal intubation was performed by the same experienced anaesthesiologist and connected to mechanical ventilation.

Data were collected manually. Statistical analysis was performed using SPSS ver. 22. Inferential statistics were performed using t-test for quantitative variables, chi-square for qualitative and ANOVA for qualitative and quantitative comparisons. Non-parametric statistical tests were used when necessary. Confidence intervals were estimated at a level of 95% and a P value of \<.05 was considered statistically significant.
After providing informed consent, participants will complete a series of questionnaires related to their headaches and medication beliefs. After completion, they will have full access to an informational website including access to text-based supplemental materials pertaining to headache and headache treatment, and a series of videos designed specifically for this trial. Participants will be asked to watch seven videos of approximately four-minute length each and to complete a post-assessment question following the completion of each of the first 6 videos. The total time required to complete all study activities will be approximately one hour.
Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on day 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
To effectively address the mental health risks associated with public health emergencies, it is crucial to actively manage rumors. This study explores the dynamic evolutionary process of rumor diffusion and its collaborative governance in public health emergencies. A game-theoretic model is constructed, involving three main actors: regulators, parties involved in public health emergencies (PIPHE), and whistle-blowers. The behaviors and game outcomes of each party are analyzed, and the effectiveness and feasibility of the model are validated through numerical simulations. The findings of this study reveal that various factors, such as regulatory costs, penalty income, reputation damage for regulators; image loss, reputation enhancement, penalty expenditure for PIPHE; and time costs, social responsibility, and reward income for whistle-blowers, all influence the behavioral choices and game equilibrium of each party. Optimization strategies for rumor governance are proposed in this study, including enhancing the sense of responsibility and capability among regulators, increasing transparency and credibility among PIPHE, and encouraging and protecting the participation of whistle-blowers. This study provides a comprehensive analytical framework for rumor governance in public health emergencies, contributing to improving the governance of public health emergencies and maintaining online public health orders for social sustainability.